Background
Abstract Background
Oral squamous cell carcinoma (OSCC) is a relatively common epithelial malignancy, and thus represents a significant public health problem. Early detection improves quality of life for affected patients. Identification of molecular markers (or biomarkers) which can predict disease progression is necessary for better management of these disorders. A correlation of cholinesterase with tumourigenesis, cell proliferation and cell differentiation has been observed. Butyrylcholinesterase (BChE; pseudocholinesterase) has been shown to be a biochemical marker for cervical cancer which is also an epithelial malignancy. In this study, we sought to estimate and compare serum BChE levels in healthy controls and patients with biopsy-proven oral squamous cell cancer (also an epithelial malignancy) before definitive therapy as radiotherapy or chemotherapy may alter the levels of BChE and may act as a confounding variable.
Method
After obtaining consent from biopsy proven oral cancer patients (n= 39) (before onset of any definitive treatment), and from age-and sex-matched healthy controls (n = 20), 2ml of blood was collected. After clot formation samples were centrifuged, serum was collected for estimation of BChE.
Results
Pre-treatment serum BChE levels were significantly elevated (p < 0.0001) in oral cancer patients compared to that of controls. BChE levels showed a significant increase (p = 0.005) with advancing stage in oral cancer patients.
Conclusion
Our results show there could be a role for serum BChE in determining the prognosis of oral cancer.
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Background
Oral cancer is the eighth most common cancer worldwide 1 and its prevalence is high among men. In India, the age standardised incidence rate of oral cancer is 12.6 per 100,000 population. 2 The term 'oral' cancer includes cancers of the lip, tongue, gingiva, oral mucosa, oropharynx and hypopharynx. proliferation and cell differentiation has been observed. [10] [11] [12] [13] Studies have shown that levels of butyrylcholinesterase (BChE; pseudocholinesterase) can be used as a biochemical marker in the management of head, neck and cervical cancer. 14 So we sought to estimate and compare serum BChE levels in healthy controls and biopsy proven oral cancer patients before definitive therapy and evaluate their role in predicting the progression of oral cancer.
Method
The study was carried out after obtaining approval from the institutional ethics committee. The subjects were oral For control: subjects with coexisting diseases; subjects on long-term medications.
We collected 2ml of blood in a vacutainer with no anticoagulant from controls and from cancer patients (before they underwent radiotherapy). The sample was allowed to clot for 30 minutes. After centrifugation at 3,000rpm for five minutes, the clear supernatant serum was used for the determination of BChE levels. BChE levels of samples were measured by using Genesis 10 UV (Thermo Electron Corporation). For maintaining the reaction temperature at 37°C, an automated water bath obtained from Rotek was used. Cyber scan 510 pH metre (Elico Ltd) was used. Sartorius balance was used for weighing chemicals.
BChE assay
Principle:
Acylthiocholine is hydrolysed by BChE to corresponding fatty acid and thiocholine. The rate of formation of Table   2 ). Bonneferoni correction for alpha error is used for multiple pair wise comparisons.
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Discussion
Extensive biochemical studies have been carried out on tumour tissue and peripheral blood to explore the aetiology of cancers and to establish tumour markers as an adjunct for establishing the diagnosis and prognosis of disease. 27 We also found increasing levels of serum BChE with advancing cancer
Limitations: The findings of our study cannot be generalised as the sample size is very small. Group characteristics included in the exclusion criteria are confounders for serum BChE levels. So, if these subjects were included in the study, there could have been a possibility of a different result from the present. One has to continue this study in a larger sample to further substantiate our findings. Since the study period was limited to one year we could not get a larger sample to suit our inclusion and exclusion criteria.
Conclusion
In this study, a significant increase in pre-treatment BChE levels in oral cancer patients as compared to controls was observed. In the oral cancer patients, pre-treatment BChE levels increased with increasing stages of tumour. Thus, BChE may have a role as a prognostic marker of oral cancer.
But this has to be ascertained by doing prospective studies in large samples. Serial estimations of BChE during the course of treatment and during the follow-up period after completion of treatment may prove more valuable in further ascertaining the role of this enzyme in the management of oral cancer.
